Professor, Department of Pharmacy,
BITS Pilani, Pilani Campus
# | Name | Thesis Title | Year started | Funding |
1 | Dr. Vigneshwaran Pitchaimani | Alternate day fasting resembles recurrent insulin-induced hypoglycemia model in rat | April 2018 to March 2020 | SERB-NPDF |
2 | Dr. Vivek Akhouri | Interdisciplinary life science programme for advanced research and education in epigenetics and genome editing | 29 August 2022 | DBT-BUILDER |
S.No | Name | Thesis Title | Year started | Status |
1 |
Mr. Almesh Kadakol
(Supervisor)
|
Role of angiotensin II on vascular epigenetics in the development of atherosclerosis and therapeutic intervention of esculetin under type 2 diabetic conditions associated with renal failure | Feb 2013 | Completed on 23rd April 2018 |
2 |
Mr. Santosh Kumar Goru (Supervisor)
|
Role of histone ubiquitination and ACE2 activation in the progression of renal fibrosis in type I diabetic kidney | Jan 2014 | Completed on 9th Jan 2018 |
3 |
Ms. Anuradha Pandey
(Supervisor) |
Role of epigenetics in modulating inflammatory response mediated by NF-kB through AT1 or AT2 receptor in the development of renal failure under type II diabetic condition | Jan 2014 | Completed on 21st March 2018 |
4 |
Mr. Malek Vajir
(Supervisor) |
Role of neprilysin in the development of cardiovascular and renal complications associated with type 1 diabetes. | Jan 2015 |
Completed on 5th Feb 2020
|
5 |
Ms. Nisha Sharma
(Supervisor) |
Involvement of Histone H3 Methylation, Angiotensin converting enzyme 2, and Angiotensin II type 2 receptor in the pathogenesis of acute kidney injury under type 1 diabetic and non-diabetic conditions | Jan 2016 | Completed on 22nd October 2020 |
6 |
Mr. Himanshu Sankrityayan (Supervisor)
|
Understanding the role and regulation of endoplasmic stress in the development of endothelial dysfunction and kidney disease under type 1 diabetic condition | July 2018 | Completed on 27th September 2022 |
7 |
Mr. Prabhjeet Singh
(Co-supervisor)
|
Actively targeted nano-carrier system for the co-delivery of temozolomide and an autophagy modulator for the treatment of glioblastoma multiforme | Dec 2019 | Work in pogress |
8 |
Mr. Ajinath Kale
(Supervisor) |
Klotho regulation as a novel therapeutic strategy against acute kidney injury-diabetes comorbidity | Jan 2020 | Completed on 4th August 2023 |
9 |
Mr. Vishwadeep Shelke
(Supervisor) |
Inflammation Targeted Pharmacotherapy for Diabetic Acute Kidney Injury: Exploring Novel Combinations | Oct 2020 | Thesis Submitted on 24th April 2024 |
10 | Ms. Ankita Sharma (Co-supervisor) |
Understanding hyperglycemia-induced epigenetic alterations contributing to drug resistance and progression of human pancreatic cancer | Dec 2020 | Work in progress |
11 |
Ms. Neha Dagar
(Supervisor) |
Evaluating the role and putative mechanisms of selected nutraceuticals against acute kidney injury under diabetic condition based on network pharmacology approach and experimental validation | Sept 2021 | Work in progress |
12 |
Ms. Shikha Thakur
(Co-Supervisor) |
Design, spynthesis, and biological evaluation of Angiotensin II type 1 receptor (AT1R) – neprilysin (NEP) inhibitors (ARNi) against diabetic cardiomyopathy (DCM) | Sept 2021 | Work in progress |
S.No | Name | Thesis title | Year |
1 | Mr. Jaspreet Singh | To evaluate the hepatoprotective and hepatocurative activity of Punica Granatum peels | 2013 |
2 | Mr. Virendra Singh | Life Saving Potential of NMD 04 Intravenous Fluid Against Animal Models of Hemorrhagic Shock | 2013 |
3 | Mr. Vishakh Prabhkar | Biological clock and Parkinsonism: Influence of the neurohormone, melatonin on experimental model of Parkinson’s disease (Co-supervisor) | 2014 |
4 | Mr. Shreyash Bagal | To study the expression of angiotensin – II (AT1 & AT2) receptors, oxidative stress and fibrotic markers in the aorta of type II diabetic rats. | 2015 |
5 | Ms. Vibha Kumari | To study the different animal models for AKI | 2018 |
6 | Ms. Jyotima Mishra | Role PARP inhibitors in Fibrosis | 2018 |
7 | Ms. Niharika Shiva | Simultaneous activation of ACE2 and ER stress inhibition in the development of type 1 diabetic cardiomyopathy | 2020 |
8 | Ms. Pooja Dhileepkumar Rao |
Role of ER stress inhibition and ACE2 activation in endothelial dysfunction under hyperglycemic condition
|
2020 |
9 | Mr. Tahib Habshi | Evaluating the renoprotective role of hinokitiol against acute kidney injury under diabetic condition | 2023 |
S.No | Name | Thesis/Project title | Year |
1 | Mr. Monil Thakkar | cGMP for Phase I Investigational Drugs | 2011 |
2 | Ms. Masuma Hasan | Good manufacturing practices For processing of mesenchymal Stromal cells | 2011 |
3 | Ms. Anjana Ramnath | Current Good Manufacturing Practices for Positron Emission Tomography Drugs | 2011 |
4 | Mr. Karthik Gangavarapu | The Cure: Developing an interactive decision tree builder for breast cancer survival prediction. (Co-supervisor) | 2014 |
5 | Ms. Garima | Partial Parallelization of de novo genome assembler. (Co-supervisor) | 2015 |
6 | Mr. Priyank Raj | Role of Epigenetics in the development of liver dysfunction under Type II Diabetic conditions | 2016 |
7 | Ms. Ananya | Role hyperglycemia in kidney injury | 2017 |
8 | Mr. Lakshya Sharma | The preclinical and clinical status of Klotho: A review of its therapeutic potential in acute and chronic kidney diseases | 2023 |
S.No | Name | Thesis/Project title | Year |
1 | Ms. Anshima Sharma | Clinical outcomes of SGLT2 inhibitors alone and in combination with existing antidiabetic and cardiovascular therapies: an update | 2021 |
2 | Mr. Uma Mahesh | Epigenetic regulation of ER stress and autophagy in kidney disease | 2021 |
3 | Ms. Anjana S. | Herbal medicine-the future of diabetic nephropathy treatment | 2021 |
4 | Mr. Tahib Habshi | Role of endoplasmic reticulum stress and autophagy in acute kidney injury to chronic kidney disease transition | 2022 |
5 | Ms. Tathamika Sen | Novel promising therapeutic targets for kidney diseases: Emphasis on kidney-specific proteins | 2022 |
6 | Ms. Soumya Sikka | Role of lncRNAs in the regulation of ER stress in AKI/Kidney diseases | 2022 |
7 | Mr. Vinayak Yelgonde | Epigenetic regulation of organelle dynamics in kidney diseases | 2022 |
8 | Ms. Swati Mishra | Immunosuppression in AKI: What to prefer or to avoid | 2023 |
9 | Mr. Mayur Chandanani | Future therapeutics and biomarkers for diabetic kidney disease: A clinical review | 2023 |
10 | Ms. Shruti Shreya | Future therapeutics for type 1 diabetes: A clinical review | 2023 |
11 | Ms. Shubhangi Saxena | Unveiling the therapeutic potential of metabolic reprogramming targeted therapies in kidney diseases | 2023 |
This website uses cookies or similar technologies, to enhance your browsing experience.